Ogier advises biotech healthcare company MiRXES Pte Ltd on US$77 million Series C financing

Ogier's corporate team in Hong Kong has acted as Cayman counsel to MiRXES Pte Ltd (MiRXES) for its US$77 million Series C financing. MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests.

This Series C financing will accelerate the company's push to deliver cancer early detection tests and preventive healthcare globally. It also brings the total amount secured by MiRXES, since its inception in 2014, to US$120 million, which marks the largest funding to date raised by a Singapore-headquartered cancer diagnostics company.

The Ogier team, led by partner Nathan Powell and managing associate Cecilia Li, provided Cayman legal advice. They worked alongside Davis Polk & Wardwell who acted for MiRXES as its Hong Kong counsel.

This Series C funding was led by CR-CP Life Science Fund, joined by global healthcare investment firm Rock Springs Capital and Singapore-based global investor EDBI and established financial institutions from the United States, Singapore, China and Hong Kong including, among others, CCBI and Keytone Ventures.

Ogier Global also provided Cayman corporate administration services to MiRXES.